A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of BTRC4017A Administered Intravenously in Patients With Locally Advanced or Metastatic HER2-Expressing Cancers

What is the purpose of this trial?

This study will evaluate the safety, tolerability, and pharmacokinetics of BTRC4017A in participants with locally advanced or metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-expressing cancers.

Genentech, Inc.

Start Date: 06/20/2018

End Date: 01/01/2020

Last Updated: 05/08/2019

Study HIC#: 2000022509

Get Involved

For more information about this study, contact:
Stephanie Rosini
+1 203-785-2963

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image


Patricia LoRusso

Principal Investigator